CRD007 for the Treatment of Abdominal Aorta Aneurysm (The AORTA Trial)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01354184
Recruitment Status : Completed
First Posted : May 16, 2011
Last Update Posted : November 6, 2012
Information provided by:
RSPR Pharma AB

Brief Summary:
This is an investigation of the efficacy and safety of CRD007 compared to placebo in the treatment of patients with abdominal aortic aneurysm.

Condition or disease Intervention/treatment Phase
Abdominal Aortic Aneurysm Drug: CRD007 Drug: CRD007 matching placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Official Title: An International, Multi-centre, Randomised, Stratified, Double-blinded, Placebo-controlled, 4-parallel Group Trial Investigating the Efficacy and Safety of Three Different Dose Levels of CRD007 (The AORTA Trial)

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: CRD007 10 mg tablet Drug: CRD007
Experimental: CRD007 25 mg tablet Drug: CRD007
Experimental: CRD007 40 mg tablet Drug: CRD007
Placebo Comparator: CRD007 matching placebo tablet Drug: CRD007 matching placebo

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Infra-renal abdominal aortic aneurysm

Exclusion Criteria:

  • Previous infra-renal aortic surgery
  • Known diabetes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01354184

Aalborg Hospital, Department of Vascular Surgery V
Aalborg, Denmark, 9000
Aarhus Universitetshospital Skejby, Hjerte-Lunge-Kar kir. afd. T
Aarhus, Denmark, 8200 N
Rigshospitalet, Karkirurgisk afdeling RK 3111
Copenhagen, Denmark, 2100 Ø
Sygehus Lillebælt, Karkirurgisk Forskningsenhed
Kolding, Denmark, 6000
Regionshospitalet Viborg, Karkiurgisk Forskningssektion
Viborg, Denmark, 8800
Borås Hospital, Department of Surgery
Borås, Sweden, 501 82
Mälarsjukhuset, Team Kärl Kir. Klin.
Eskilstuna, Sweden, 631 88
Sahlgrenska Universitetssjukhuset
Göteborg, Sweden, 413 45
Skånes Universitets Sjukhus, Institution of Surgical Science
Malmo, Sweden, 205 02
Universitetssjukhuset Örebro, Kirurgkliniken, Kärlsektionen
Orebro, Sweden, 701 85
Karolinska University Hospital, Kärlkirurgiska Kliniken
Stockholm, Sweden, 171 76
Uppsala University Hospital
Uppsala, Sweden, 751 85
Centrallaserettet, Kärlkirurgiska Kliniken
Västerås, Sweden, 721-89
United Kingdom
St George's Hospital NHS Trust
London, United Kingdom, SW17 0Qt
University Hospital of South Manchester
Manchester, United Kingdom, M23 9LT
Sponsors and Collaborators
RSPR Pharma AB
Principal Investigator: Henrik Sillesen, MD DMSc Rigshospitalet, University of Copenhagen, Denmark

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT01354184     History of Changes
Other Study ID Numbers: Cardoz-003
First Posted: May 16, 2011    Key Record Dates
Last Update Posted: November 6, 2012
Last Verified: November 2012

Additional relevant MeSH terms:
Aortic Aneurysm
Aortic Aneurysm, Abdominal
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases